Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
Explaining building damage from wildfires in California.
Journal: Science advances
Published: July 24, 2026
Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.
Journal: Journal of the American Academy of Dermatology
Published: February 24, 2026
Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: February 20, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 13, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.
Journal: The Journal of dermatology
Published: February 04, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.
Journal: The British journal of dermatology
Published: January 30, 2026
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
Journal: The New England journal of medicine
Published: November 05, 2025
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.
Journal: NEJM evidence
Published: November 05, 2025
A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis.
Journal: Annals of the rheumatic diseases
Published: September 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.
Journal: The Journal of dermatological treatment
Published: July 15, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Journal: Lancet (London, England)
Published: July 08, 2025
Last Updated: 09/26/2026